

David A Cairns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3514849/publications.pdf>

Version: 2024-02-01

121
papers

4,641
citations

109321

35
h-index

110387

64
g-index

123
all docs

123
docs citations

123
times ranked

6926
citing authors

#	ARTICLE	IF	CITATIONS
1	Redefining nonmeasurable multiple myeloma using mass spectrometry. <i>Blood</i> , 2022, 139, 946-950.	1.4	11
2	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. <i>Journal of Clinical Oncology</i> , 2022, 40, 2889-2900.	1.6	29
3	Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 287-293.	1.0	8
4	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	1.6	115
5	Frailty-adjusted therapy in transplant-ineligible patients with newly diagnosed Multiple Myeloma (FiTNess (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , 2022, 12, e056147.	1.9	11
6	Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. <i>Blood Advances</i> , 2022, 6, 5113-5123.	5.2	3
7	Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021, 35, 2043-2053.	7.2	23
8	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 551-555.	2.5	25
9	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021, 192, 853-868.	2.5	14
10	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003454.	8.4	18
11	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. <i>Clinical Hematology International</i> , 2021, 3, 27.	1.7	1
12	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 667-675.	0.4	12
13	Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2021, 7, 869.	7.1	83
14	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. <i>Haematologica</i> , 2021, 106, 2754-2758.	3.5	45
15	The development and validation of prognostic models for overall survival in the presence of missing data in the training dataset: a strategy with a detailed example. <i>Diagnostic and Prognostic Research</i> , 2021, 5, 14.	1.8	1
16	Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population—Reply. <i>JAMA Oncology</i> , 2021, 7, 1725.	7.1	1
17	Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	0
18	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , 2020, 34, 604-612.	7.2	56

#	ARTICLE	IF	CITATIONS
19	Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. <i>Blood Advances</i> , 2020, 4, 5836-5845.	5.2	7
20	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMJ Open</i> , 2020, 10, e034527.	1.9	11
21	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	3.5	16
22	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , 2020, 34, 3091-3096.	7.2	26
23	<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2422-2432.	7.0	37
24	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020, 136, 1091-1104.	1.4	58
25	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , 2020, Online ahead of print, 0-0.	3.5	16
26	Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e028613.	1.9	2
27	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e616-e629.	4.6	42
28	The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from <sc>BSBMT</sc>/<sc>UKMF</sc> Myeloma X) Tj ETQg 0 0 rgBT /Overloc 450-467.	2.5	14
29	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019, 104, 1440-1450.	3.5	67
30	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. <i>Lancet Haematology</i> , 2019, 6, e154-e166.	4.6	71
31	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 57-73.	10.7	245
32	Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. <i>Journal of Pathology</i> , 2019, 247, 381-391.	4.5	33
33	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. <i>International Journal of Cardiology</i> , 2018, 266, 7-14.	1.7	41
34	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. <i>Leukemia</i> , 2018, 32, 102-110.	7.2	177
35	Rate-Response Programming Tailored to the Force-Frequency Relationship Improves Exercise Tolerance in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 105-113.	4.1	14
36	Subclonal TP53 copy number is associated with prognosis in multiple myeloma. <i>Blood</i> , 2018, 132, 2465-2469.	1.4	29

#	ARTICLE	IF	CITATIONS
37	Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrology, 2018, 19, 178.	1.8	24
38	Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma <scp>IX</scp> randomised study. British Journal of Haematology, 2018, 182, 816-829.	2.5	23
39	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 2018, 19, 169.	1.6	8
40	1â€...Coronary microvascular dysfunction in stable coronary artery disease: the CE-MARC 2 coronary physiology sub-study. , 2018, , .		0
41	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
42	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 2018, 32, 1727-1738.	7.2	50
43	Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival â€” Data from the Ukmrc Myeloma XI Trial. Blood, 2018, 132, 122-122.	1.4	5
44	Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. Blood, 2018, 132, 255-255.	1.4	4
45	A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. Blood, 2018, 132, 302-302.	1.4	6
46	The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. Health Technology Assessment, 2018, 22, 1-274.	2.8	27
47	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants for Applied Research, 2018, 6, 1-528.	1.0	3
48	Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. Blood, 2018, 132, 2000-2000.	1.4	0
49	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. Blood, 2018, 132, 3280-3280.	1.4	2
50	Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. British Journal of Haematology, 2017, 178, 220-230.	2.5	34
51	Cardiac resynchronization therapy outcomes in patients with chronic heart failure. Journal of Cardiovascular Medicine, 2017, 18, 962-967.	1.5	10
52	Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, 2017, 130, 1639-1643.	1.4	20
53	Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematology,the, 2017, 4, e584-e594.	4.6	6
54	89â€...Development and external validation of a multivariable model of pre-test likelihood of coronary artery disease based on a contemporary uk population, with comparison to existing risk models. Heart, 2017, 103, A64.3-A66.	2.9	0

#	ARTICLE	IF	CITATIONS
55	Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study.. Journal of Clinical Oncology, 2017, 35, 8009-8009.	1.6	10
56	Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification. Heart, 2016, 102, 735-740.	2.9	3
57	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 2016, 6, e506-e506.	6.2	68
58	Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart Failure. Journal of the American College of Cardiology, 2016, 67, 1885-1896.	2.8	32
59	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematology, 2016, 3, e340-e351.	4.6	120
60	Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates. JAMA - Journal of the American Medical Association, 2016, 316, 1051.	7.4	227
61	Reply. Journal of the American College of Cardiology, 2016, 68, 1819-1820.	2.8	0
62	The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clinical Cancer Research, 2016, 22, 5783-5794.	7.0	81
63	Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, 2016, 30, 883-888.	7.2	11
64	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 2016, 108, .	6.3	75
65	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 1009-1016.	2.0	8
66	Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nature Communications, 2016, 7, 10290.	12.8	31
67	Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study. Blood, 2016, 128, 1143-1143.	1.4	26
68	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). Blood, 2016, 128, 4412-4412.	1.4	2
69	miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nature Communications, 2015, 6, 8725.	12.8	88
70	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 2015, 6, 6997.	12.8	261
71	Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2015, 33, 3911-3920.	1.6	463
72	An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis. Proteomics - Clinical Applications, 2015, 9, 507-521.	1.6	15

#	ARTICLE	IF	CITATIONS
73	Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. <i>Blood</i> , 2015, 126, 1847-1847.	1.4	1
74	Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. <i>Blood</i> , 2015, 126, 189-189.	1.4	4
75	Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 371-371.	1.4	5
76	A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. <i>Blood</i> , 2015, 126, 394-394.	1.4	4
77	Statistical Issues in the Design and Planning of Proteomic Profiling Experiments. <i>Methods in Molecular Biology</i> , 2015, 1243, 223-236.	0.9	0
78	Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial. <i>Blood</i> , 2015, 126, 1981-1981.	1.4	20
79	Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients. <i>Blood</i> , 2015, 126, 2983-2983.	1.4	0
80	Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience. <i>Blood</i> , 2015, 126, 3180-3180.	1.4	0
81	Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and) Tj ETQq1 1 0.784314 rgBT/Overl	1.4	0
82	Biomarkers and Response to Bevacizumab Response. <i>Clinical Cancer Research</i> , 2014, 20, 1058-1058.	7.0	1
83	Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 243-251.	2.9	12
84	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 5 15, 874-885.	10.7	139
85	The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact. <i>Blood</i> , 2014, 124, 2194-2194.	1.4	2
86	Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients. <i>Blood</i> , 2014, 124, 637-637.	1.4	1
87	Treating diabetic patients with chemotherapy: Single-center experience of toxicity and outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9643-9643.	1.6	0
88	Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8537-8537.	1.6	0
89	Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA. <i>Blood</i> , 2014, 124, 5168-5168.	1.4	0
90	The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment. <i>Blood</i> , 2014, 124, 640-640.	1.4	0

#	ARTICLE	IF	CITATIONS
91	High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation. <i>Blood</i> , 2014, 124, 2189-2189.	1.4	0
92	High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients. <i>Blood</i> , 2014, 124, 172-172.	1.4	0
93	Retinoic acid-induced protein 3: Identification and characterisation of a novel prognostic colon cancer biomarker. <i>European Journal of Cancer</i> , 2013, 49, 531-539.	2.8	39
94	Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. <i>Kidney International</i> , 2013, 84, 1214-1225.	5.2	47
95	Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. <i>Clinical Cancer Research</i> , 2013, 19, 5227-5239.	7.0	63
96	Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: Assessment of overall technical variability and the impact of block age. <i>Proteomics - Clinical Applications</i> , 2013, 7, 273-282.	1.6	45
97	The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. <i>Blood</i> , 2013, 122, 3378-3378.	1.4	1
98	A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. <i>Blood</i> , 2013, 122, 765-765.	1.4	1
99	NuMA Overexpression in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2012, 7, e38945.	2.5	21
100	Initial Development and Validation of a Novel Extraction Method for Quantitative Mining of the Formalin-Fixed, Paraffin-Embedded Tissue Proteome for Biomarker Investigations. <i>Journal of Proteome Research</i> , 2011, 10, 896-906.	3.7	75
101	ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. <i>British Journal of Cancer</i> , 2011, 104, 1602-1610.	6.4	67
102	The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2011, 284, 221-227.	1.7	28
103	A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease. <i>Proteomics - Clinical Applications</i> , 2011, 5, 523-531.	1.6	6
104	Statistical issues in quality control of proteomic analyses: Good experimental design and planning. <i>Proteomics</i> , 2011, 11, 1037-1048.	2.2	48
105	A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. <i>Proteomics</i> , 2011, 11, 2222-2235.	2.2	64
106	Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. <i>British Journal of Cancer</i> , 2010, 103, 101-111.	6.4	47
107	The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 5070-5070.	1.6	1
108	Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. <i>British Journal of Cancer</i> , 2009, 101, 1175-1182.	6.4	33

#	ARTICLE	IF	CITATIONS
109	Analysis of <i>VHL</i> Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 7582-7592.	7.0	160
110	Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. <i>Proteomics</i> , 2009, 9, 74-86.	2.2	56
111	Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles – initial evaluation using low molecular weight serum peaks. <i>Proteomics</i> , 2009, 9, 492-498.	2.2	20
112	Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. <i>Proteomics</i> , 2009, 9, 2118-2130.	2.2	31
113	Changes in the urinary proteome postoperatively in renal cancer patients – a reflection of tumour or kidney removal?. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1112-1122.	1.6	3
114	Proteomic profiling using mass spectrometry – does normalising by total ion current potentially mask some biological differences?. <i>Proteomics</i> , 2008, 8, 21-27.	2.2	30
115	Serum biomarker discovery in renal cancer using 2DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?. <i>Proteomics</i> , 2008, 8, 5074-5085.	2.2	33
116	Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. <i>BMC Bioinformatics</i> , 2008, 9, 519.	2.6	19
117	Application of the Random Forest Classification Method to Peaks Detected from Mass Spectrometric Proteomic Profiles of Cancer Patients and Controls. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2008, 7, Article4.	0.6	25
118	Characterization of Home Range Using Point Peeling Algorithms. <i>Journal of Wildlife Management</i> , 2006, 70, 422-434.	1.8	6
119	Urinary biomarker profiling in transitional cell carcinoma. <i>International Journal of Cancer</i> , 2006, 119, 2642-2650.	5.1	84
120	Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry. <i>Clinical Chemistry</i> , 2005, 51, 1637-1649.	3.2	225
121	Association of genetic variants with patient reported quality of life and pain experience in patients in O, , .	2.4	1